Clinical severity of COVID-19 patients admitted to hospitals during the Omicron wave in South Africa
Authors:
- Waasila JassatWJWaasila Jassat
- Salim S Abdool KarimSKSalim S Abdool Karim
- Caroline MudaraCMCaroline Mudara
- Lovelyn OzougwuLOLovelyn Ozougwu
- Michelle J. GroomeMGMichelle J. Groome
- Nevashan GovenderNGNevashan Govender
- Anne von GottbergAGAnne von Gottberg
- Nicole WolterNWNicole Wolter
- Milani WolmaransMWMilani Wolmarans
- Petro RousseauPRPetro Rousseau
- DATCOV author groupDGDATCOV author group
Preprint
Abstract
Background Clinical severity of patients hospitalised with SARS-CoV-2 infection during the Omicron (fourth) wave was assessed and compared to trends in the D614G (first), Beta (second), and Delta (third) waves in South Africa. Methods Weekly incidence of 30 laboratory-confirmed SARS-CoV-2 cases/100,000 population defined the start and end of each wave. Hospital admission data were collected through an active national COVID-19-specific surveillance programme. Disease severity was compared across waves by post-imputation random effect multivariable logistic regression models. Severe disease was defined as one or more of acute respiratory distress, supplemental oxygen, mechanical ventilation, intensive-care admission or death. Results 335,219 laboratory-confirmed SARS-CoV-2 admissions were analysed, constituting 10.4% of 3,216,179 cases recorded during the 4 waves. In the Omicron wave, 8.3% of cases were admitted to hospital (52,038/629,617) compared to 12.9% (71,411/553,530) in the D614G, 12.6% (91,843/726,772) in the Beta and 10.0% (131,083/1,306,260) in the Delta waves (pConclusion The trend of increasing cases and admissions across South Africa’s first three waves shifted in Omicron fourth wave, with a higher and quicker peak but fewer admitted patients, who experienced less clinically severe illness and had a lower case-fatality ratio. Omicron marked a change in the SARS-CoV-2 epidemic curve, clinical profile and deaths in South Africa. Extrapolations to other populations should factor in differing vaccination and prior infection levels.Keywords
All Related Versions
- Published version: The Lancet Global Health, 10 (7), e961.
This publication has 15 references indexed in Scilit:
- South African Population Immunity and Severe Covid-19 with Omicron VariantmedRxiv, 2021
- Track Omicron’s spread with molecular dataScience, 2021
- Covid-19 Vaccine Effectiveness in New York StateNew England Journal of Medicine, 2021
- Severity of SARS-CoV-2 Reinfections as Compared with Primary InfectionsNew England Journal of Medicine, 2021
- Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South AfricamedRxiv, 2021
- Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort studyThe Lancet Global Health, 2021
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 VariantNew England Journal of Medicine, 2021
- New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine ImplicationsNew England Journal of Medicine, 2021
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionScience, 2021
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020